e-learning
resources
Paris 2018
Tuesday, 18.09.2018
Role of microbial exposure and inflammation in lung injury
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of ASA and DHA therapy on malaria associated ARDS
H. Oliveira (Rio de Janeiro, Brazil), C. Batista (Rio de Janeiro, Brazil), M. Lima (Rio de Janeiro, Brazil), E. Amorim (Rio de Janeiro, Brazil), A. Silva (Rio de Janeiro, Brazil), T. Maron-Gutierrez (Rio de Janeiro, Brazil), H. Castro-Faria-Neto (Rio de Janeiro, Brazil)
Source:
International Congress 2018 – Role of microbial exposure and inflammation in lung injury
Session:
Role of microbial exposure and inflammation in lung injury
Session type:
Thematic Poster
Number:
4291
Disease area:
Airway diseases, Respiratory critical care
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Oliveira (Rio de Janeiro, Brazil), C. Batista (Rio de Janeiro, Brazil), M. Lima (Rio de Janeiro, Brazil), E. Amorim (Rio de Janeiro, Brazil), A. Silva (Rio de Janeiro, Brazil), T. Maron-Gutierrez (Rio de Janeiro, Brazil), H. Castro-Faria-Neto (Rio de Janeiro, Brazil). Effects of ASA and DHA therapy on malaria associated ARDS. 4291
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The effect of conjugated linoleic acid supplementation on the nutritional status of COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Effect of antibiotic prophylaxis on pneumonia in cardiac arrest patients treated with therapeutic hypothermia
Source: Annual Congress 2012 - Infections and sepsis in the ICU
Year: 2012
Effects of high dose N-acetylcysteine in COPD patients
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Cardiovascular effects of high dose N-acetylcysteine in severe pneumonia-induced sepsis
Source: Eur Respir J 2003; 22: Suppl. 45, 452s
Year: 2003
LSC Abstract – Effects of vitamin D supplementation on perioperative markers of inflammation in patients at risk of acute respiratory distress syndrome (ARDS)
Source: International Congress 2016 – New therapies and therapeutic targets
Year: 2016
Effect of daily azithromycin therapy and adherence on readmission risk in COPD
Source: Eur Respir J, 53 (3) 1801377; 10.1183/13993003.01377-2018
Year: 2019
Efficacy of surfactant-BL in treatment ARDS in patients with severe inhalation injury
Source: Eur Respir J 2006; 28: Suppl. 50, 345s
Year: 2006
Exogenous surfactant administration in patients at high risk to develop ARDS after multiple trauma
Source: Eur Respir J 2001; 18: Suppl. 33, 7s
Year: 2001
Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019
Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
Effect of azithromycin treatment on inflammation in COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Effect of oral N-acetylcysteine treatment on systemic inflammatory status in COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 716s
Year: 2005
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Influence of inhaled bronchodilator therapy on bacterioexcretion and LQ in patients with pulmonary TB infection with concomitant broncho-obstructive syndrome
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Effect of low dose theophylline as adjunct in treatment of COPD
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Increased platelet reactivity during acute exacerbations of COPD, irrespective of antiplatelet therapy
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Effect of erdosteine in moderately severe COPD patients
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
High doses of N-acetylcysteine alone or in combination with inhaled corticosteroids and oxidative stress in patients with COPD
Source: Annual Congress 2011 - Novel mechanisms in lung injury
Year: 2011
Low risk of adrenal dysfunction in children with severe asthma treated with high-dose inhaled glucocorticoids
Source: Eur Respir J 2005; 26: Suppl. 49, 161s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept